Published in J Neural Transm (Vienna) on March 01, 2002
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage (2006) 1.92
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
The effect of age of onset of PD on risk of dementia. J Neurol (2007) 1.14
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
The natural history of Parkinson's disease. J Neurol (2006) 1.05
Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol Aging (2006) 1.00
Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord (2014) 0.93
Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 0.93
Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord (2011) 0.92
Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry (2007) 0.89
Neuroimaging in Parkinson's disease. NeuroRx (2004) 0.88
Cognitive profiles of patients with mild cognitive impairment or dementia in Alzheimer's or Parkinson's disease. Dement Geriatr Cogn Dis Extra (2013) 0.84
Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm (Vienna) (2011) 0.84
Characteristics of MR infarcts associated with dementia and cognitive function in the elderly. Neuroepidemiology (2011) 0.84
Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain. Parkinsons Dis (2012) 0.83
Parkinson's disease dementia: a diminished role for the Lewy body. Parkinsonism Relat Disord (2009) 0.83
Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice. Dis Model Mech (2012) 0.82
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis (2012) 0.82
Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm (Vienna) (2008) 0.81
An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS One (2016) 0.81
Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm (Vienna) (2012) 0.79
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol (2016) 0.79
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol (2017) 0.77
Differences between conventional and nonconventional MRI techniques in Parkinson's disease. Funct Neurol (2013) 0.77
Functional neuroimaging in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.77
Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia. J Mov Disord (2010) 0.76
Tau PET imaging: present and future directions. Mol Neurodegener (2017) 0.76
Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease. Ann Gen Psychiatry (2006) 0.75
Syndromic approach to Parkinson's disease: role of functional imaging. J Clin Neurol (2006) 0.75
Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology (2016) 0.75
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) BMJ (1996) 2.42
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation (1997) 2.18
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease): three cases without evidence of "flexion myelopathy". Acta Neurol Scand (2001) 1.74
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry (2000) 1.70
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol (2012) 1.57
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Subacute dementia and imaging correlates in a case of Fahr's disease. J Neurol Neurosurg Psychiatry (2004) 1.53
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol (2002) 1.51
Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand (2003) 1.50
Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology (2007) 1.48
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation (1999) 1.46
Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology (2002) 1.46
Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther (2008) 1.45
Ataxia without telangiectasia masquerading as benign hereditary chorea. Mov Disord (1996) 1.45
Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology (2008) 1.45
Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience (2002) 1.42
Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1.41
Transient restless legs syndrome after spinal anesthesia: a prospective study. Neurology (2002) 1.39
[Vascular parkinsonian syndrome]. Nervenarzt (2006) 1.39
[Spinal fibrocartilaginous embolism]. Nervenarzt (2005) 1.39
Cortical and brain stem hyperexcitability in striatonigral degeneration. Mov Disord (1998) 1.38
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage (2000) 1.32
Influence of concurrent tasks on gait: a dual-task approach. Percept Mot Skills (1995) 1.31
The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol (2012) 1.29
Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology (2002) 1.26
Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst (1998) 1.25
Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology (2003) 1.25
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry (2004) 1.22
Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry (1995) 1.22
Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21
Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2004) 1.19
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep (2002) 1.19
Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison. Acta Neurol Scand (1995) 1.19
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry (1997) 1.17
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord (2000) 1.17
Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology (1997) 1.16
Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry (1996) 1.16
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology (2011) 1.15
The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain (2005) 1.14
Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain (1999) 1.14
The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study. J Neurol Neurosurg Psychiatry (2003) 1.14
Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain (1999) 1.14
Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Brain (1996) 1.13
Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med (2000) 1.11
Clinical and polymyographic investigation of spasmodic torticollis. J Neurol (1992) 1.11
Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem (2000) 1.10
Replication of restless legs syndrome loci in three European populations. J Med Genet (2009) 1.08
Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (1995) 1.08
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol (1995) 1.08
Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology (2006) 1.07
Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med (1997) 1.06
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
Hemimasticatory spasm in hemifacial atrophy: diagnostic and therapeutic aspects in two patients. Mov Disord (1995) 1.05
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord (1997) 1.04
Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord (1999) 1.02
Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol (2001) 1.02
Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord (1999) 1.02